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Abstract  
Introduction: Studies have shown high initial mortality in Antiretroviral Therapy (ART) programs from resource-limited settings. However, there is 
dearth of evidence on treatment outcomes and associated determinant factors in public hospitals. Therefore, the objective of this study is to assess 
survival and identify predictors of death in adult HIV-infected patients initiating ART at a public hospital in Eastern Ethiopia. Methods: A 
retrospective cohort study was conducted by reviewing baseline and follow-up records of patients who started ART between December 1, 2007 
and December 31, 2011 at Kharamara hospital. Time to death was the main outcome measure. Kaplan-Meier models were used to estimate 
mortality and Cox proportional hazards models to identify predictors of mortality. Results: A total of 784 patients (58.4% females) were followed 
for a median of 60 months. There were 87 (11.1%) deaths yielding an overall mortality rate of 5.15/100 PYO (95% CI: 4.73-6.37). The estimated 
mortality was 8.4%, 9.8%, 11.3%, 12.7% and 14.1% at 6, 12, 24, 36 and 48 months respectively. The independent predictors of death were 
single marital status (AHR: 2.31; 95%CI: 1.18-4.50), a bedridden functional status (AHR: 5.91; 95%CI: 2.87-12.16), advanced WHO stage (AHR: 
7.36; 95%CI: 3.17-17.12), BMI < 18.5 Kg/m2 (AHR: 2.20; 95%CI: 1.18-4.09), CD4 count < 50 cells/µL (AHR: 2.70; 95%CI: 1.26-5.80), severe 
anemia (AHR: 4.57; 95%CI: 2.30-9.10), and TB co-infection (AHR: 2.30; 95%CI: 1.28-4.11). Conclusion: Improved survival was observed in 
patients taking ART in Somali region of Ethiopia. The risk for death was higher in patients with advanced WHO stage, low CD4 count, low Hgb, low 
BMI, and concomitant TB infection. Intensive case management is recommended for patients with the prognostic factors. Optimal immunologic 
and weight recoveries in the first 6 months suggest increased effort to retain patients in care at this period.  
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According to the 2012 UNAIDS report, there are an estimated 34 
million People Living with HIV (PLHIV) worldwide, Sub-Saharan 
Africa (SSA) accounting for 69%, with nearly 1 in every 20 adults 
(4.9%) living with HIV; Around 1.7 million people died from AIDS-
related causes worldwide, 70% occurred in SSA [1]. Ethiopia is one 
of the hardest hit sub-Saharan African countries by the HIV 
pandemic. By the end of 2012, there were 759,268 people living 
with HIV; 41,444 deaths from AIDS-related causes and 20,158 new 
HIV infections [2]. For 2007, the estimated life expectancy was 52.5 
years, with 3.9 years lost to AIDS [3]. In January 2005, the FDRE 
Ministry of Health (MoH) launched the free ART rollout program. By 
the end of 2011 there were 249,174 patients on treatment, making 
the ART coverage for adult population of PLHIV 86% [4]. The 
introduction of HAART witnessed a decrease in AIDS-defining 
opportunistic infections, a decline in AIDS related mortalities, and 
improved survival of PLHIV. Despite increased availability of ARV 
and promising efficacy reported from ART programs in resource-
limited settings, mortality has been high particularly the first few 
months after initiating ART [5, 6]. Reporting treatment outcomes of 
patients enrolled in ART programs is important to demonstrate 
program effectiveness and justify continued funding, while 
assessment of factors associated with outcomes can help to identify 
opportunities for program improvement [7]. Few studies have 
reported baseline socio-demographic and clinical factors in 
predicting survival after ART initiation [8-10]. However, there are no 
studies describing mortality on ART and its associated factors over 
longer follow up periods. Therefore, this study determines factors 
associated with survival and progressive immunologic and weight 






Study setting: the study was conducted at Kharamara hospital, in 
Jijiga town from March to May 2013. Jijiga, the administrative 
capital of Somali region, is located 614 km to the east of Addis 
Ababa, Ethiopia's capital. The hospital provides general outpatient 
and inpatient services, surgical and obstetric emergency, and 
regional referral hospital for ophthalmologic service. In the 
comprehensive HIV care and treatment service at the hospital, there 
are 9,208 patients enrolled, of which 1,501 ever-started ART, and 
1,432 currently on ART.  
  
Study design: a retrospective cohort study was conducted to 
assess survival and determinants of mortality among PLHIV 
receiving antiretroviral therapy. A total of 784 PLHIV aged ≥15 
years, initiating ART at Kharamara hospital between December 1, 
2007 and December 31, 2011 were included in the study. The 
independent variables were socio-demographic characteristics, 
baseline clinical, laboratory and ART information. The main outcome 
measure in the study was follow-up time till Death. The second 
outcome measures were median changes in CD4 count and weight.  
  
Participants: the source population was adult HIV/AIDS patients 
who started ARV and were on follow up at the ART clinic during the 
study period. Patients who initiated treatment outside Kharamara 
hospital, women who were pregnant and lactating mothers on 
PMTCT, and patients with competing causes of death (accident, or 
any non-AIDS malignancies) were excluded. The sample size was 
determined by taking the mortality rates in two groups of PLHIV on 
ART based on their WHO clinical stage as exposure status. The 
mortality rate among exposed (WHO stage IV) is 0.3% and among 
non-exposed (WHO stage II-III), 0.1% [10]. The study participants 
were randomly selected using patients' unique identification number 
and were retrospectively followed for additional 60 months until 
December 31, 2012.  
  
Data collection and quality control: to compile the required 
information a data collection form was developed from the national 
ART intake and follow-up forms. The data were collected by 
reviewing pre-ART register, ART intake form, laboratory request, 
monthly cohort form, and follow up form. The most recent 
laboratory results before starting ART were used as a baseline 
value. If there were no pre-treatment laboratory tests, results 
obtained within one month of ART initiation were used as baseline. 
If two results were obtained within a month, their mean would be 
used. Death from all AIDS related causes was ascertained by 
reviewing patients' medical records in the hospital, or registrations 
reported by adherence supporters. The data were collected by two 
experienced ART nurses who were trained on comprehensive HIV 
care and who are working in the ART clinic at Kharamara hospital. A 
supervisor supervised the data collection process. The data 
collectors and the supervisor were trained on the data collection 
procedures for two days. The investigator oversaw the overall 
process. All completed data collection forms were examined for 
completeness, consistency and clarity during data management, 
storage, and analysis.  
  
Data analysis: data exploration was carried out to check for any 
inconsistencies, coding error, out of range, and missing values and 
appropriate corrections were made. Descriptive analyses of the 
continuous and categorical data describing the cohort's 
characteristics at baseline and during follow-up were made. Patients 
were censored on the date of any one of the following events, 
whichever occurred first: if lost to follow-up, if transferred to 
another health facility, or if alive at the end of follow up. The 
outcomes of each patient were dichotomized into censored or dead. 
Kaplan-Meier model was be used to assess survival functions 
stratified by baseline and follow up variables, and the log-rank test 
was used to assess statistical difference among groups (for equality 
of survival distributions). Cox-proportional Hazards model was used 
to identify prognostic factors of death, and to calculate their 
bivariate and adjusted hazard ratios. All analyses were conducted 






The study cohort included 784 patients with a mean age of 34 
(SD±10). Out of the total study population, 485 (58.4%) were 
females. Three hundred twenty five (41.5%) were married and 455 
(58%) had dependent children at home. Four hundred eighty seven 
(62.1%) had at least completed primary education, and 359 
(45.8%) had no occupation. The majority 431 (55%) had good ART 
adherence (see Table 1). At the time of ART initiation, 455 (58.0%) 
were in WHO clinical stage III&IV and 242 (30.9%) had an 
ambulatory functional status. Among the study participants, 449 
(57.3%) had a BMI < 18.5 Kg/m2 and 311 (39.7%) developed 
active TB infection. With regard to chemoprophylaxis, the majority 
658 (83.9%) were given cotrimoxazole and only 61 (7.8%) received 
INH. The median (IQR) weight, CD4 count and hemoglobin of the 
cohort were 50kg (44-56), 146 cells /µL (102-196) and 11.5 g/dL 
(10-13) respectively (see Table 2).  
  
Follow up  
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A total of 87 (11.1%) patients died during the five year follow-up 
period, with majority of deaths 49(56.3%) occurring in the first 3 
months (HR: 0.022). One hundred fifty seven (20.0%) patients 
were transferred to other facility and 193 (24.6%) were lost-to-
follow up. The remaining 344 (43.9%) were active until the last 
censoring date. The median survival time for event (death) was 
20.7 months (IQR, 17.5-22.6). The overall mortality rate in the 
cohort during the 1,608 person-years of observation (PYO) was 
5.15/100 PYO (95% CI: 4.73-6.37). The estimated mortality was 
8.4%, 9.8%, 11.3%, 12.7% and 14.1% at 6, 12, 24, 36 and 48 
months respectively (see Figure 1).  
  
Predictors of mortality  
  
In bivariate Cox regression analysis, sex, marital status, education 
level, functional status, WHO clinical stage, BMI, CD4 count, 
Anemia, cotrimoxazole prophylaxis, INH prophylaxis, TB co-
infection, and ART adherence were all associated with survival (P < 
0.05). In the multivariate Cox regression analysis, the independent, 
significant predictors of mortality in PLHIV on ART at Kharamara 
hospital were single marital status (AHR: 2.31; 95%CI: 1.18-4.50), 
a bedridden functional status (AHR: 5.91; 95%CI: 2.87-12.16), 
advanced WHO stage (AHR: 7.36; 95%CI: 3.17-17.12), BMI < 18.5 
Kg/m2 (AHR: 2.20; 95%CI: 1.18-4.09), CD4 count < 50 cells/µL 
(AHR: 2.70; 95%CI: 1.26-5.80), severe anemia (AHR: 4.57; 95%CI: 
2.30-9.10), and TB co-infection (AHR: 2.30; 95%CI: 1.28-4.11) (see 
Table 3).  
  
Weight and CD4 change during the follow-up  
  
Weight and CD4 recovery were used as supplementary indicators for 
comprehensive treatment outcomes. At the start of ART, the median 
weight of the cohort was 50.0 Kg. During the follow-up period, the 
median weight (IQR) at 6, 12, 24, 36, 48 and 60 months were 54 
(48-61), 55 (48-64), 56 (50-64), 56 (49-64), 57 (50-65) and 57 (50-
64), Kg., respectively (Figure 2). Similarly, the median CD4 count 
at baseline was 146cells/µL. In the follow-up period, the median 
CD4 count (IQR) changed to 258 (172-369), 286 (201-406), 351 
(246-506), 389 (270-549), 405 (302-565) and 567 (390-770) at 6, 
12, 24, 36, 48 and 60 months, respectively (Figure 3). During the 
follow-up period, 123 patients had their CD4 count declined to 
below or equal to the baseline values yielding an immunologic 





In this historical longitudinal study, there were 87 deaths in 1,608 
PYO, yielding an incidence density of 5.15/100 PYO (95%CI: 4.73-
6.37). The independent predictors of mortality include single marital 
status, being illiterate, bedridden functional status, advanced WHO 
status, low BMI, low CD4 count, severe anemia and TB co-infection. 
The estimated survival probability of the cohort at 6, 12, 24, 36 and 
48 months was 91.6%, 90.2%, 88.7%, 87.3% and 85.9%, 
respectively. This shows a better survival compared to other studies 
in Africa. According to a study in a Malawian cohort, the probability 
of being alive on ART at 6, 12 and 18 months was 89.8%, 83.4% 
and 78.8% respectively [11]. On the other hand, the death rate was 
comparable to most studies, especially, in the 1st six months [6, 8, 
9]. This might be explained by the fact that most of the patients in 
this study had advanced disease status (78% had CD4 < 200 
cells/mL and 58% were in WHO stage III & IV). Patients who were 
illiterate had high risk of mortality compared to those with college 
education or above (AHR: 4.73; 95%CI: 1.07-22.40). A study 
conducted in Ethiopia also found a strong association between level 
of education and survival [12]. Single patients had a higher risk for 
death compared to married patients (AHR: 2.31; 95%CI: 1.18-
4.50). This difference might be due to married patients' 
psychological preparedness to seek partners' and social support, 
conceive the facts, and adhere to ART [13].  
  
The result from this study shows patients with a CD4 count of < 50 
cells/mL have a higher risk of mortality (AHR: 2.70; 95%CI: 1.26-
5.80) compared to those with a CD4 count of ≥ 200 cells/mL. 
Majority of previous studies also found twice or more risk of 
mortality in patients with lower CD4 count compared to those with a 
CD4 count of ≥ 200 cells/mL [5, 12, 14]. Patients with severe 
anemia were 4.57 more at risk of death compared to those with 
normal levels. In a study from Tanzania, patients with severe 
anemia were 15 times higher at risk of dying during the first year on 
ART compared to those with a normal hemoglobin level [6]. Other 
studies have also indicated patients with low hemoglobin level (<10 
mg/dL) had increased risk of death [5, 9, 15]. Although there is no 
concrete evidence on casual association between anemia and 
mortality, the incidence of anemia increased with progression of HIV 
disease [14]. In this study also, severe anemia was associated with 
an advanced WHO stage (24.2% in Stage IV vs. 8.8% in stage 
I&II). One of the most important side effects of AZT is myelotoxicity 
leading to severe anemia [15]. In this cohort, severe anemia in 
patients taking AZT was higher (46.7%) among the dead compared 
to those censored (8.8%). In the current study, the risk of death in 
patients with a BMI < 18.5 Kg/m2 was more than two times higher 
(AHR: 2.20; 95%CI: 1.18-4.09) compared to those with a BMI < 
18.5kg/m2. Study conducted in rural Malawi showed individuals who 
were severely malnourished (BMI < 16kg/m2) had six times higher 
risk of dying in the first three months than those with a normal 
nutritional status [16]. BMI is an indicator of patient nutritional 
status but may also be influenced by late-stage AIDS conditions, 
such as wasting syndrome and opportunistic infections, or by 
progression of the HIV itself [17]. In the current cohort, there was a 
significant difference in mean BMI between TB +VE patients (18.10; 
95%CI: 17.66-18.54) and TB -VE ones (18.77; 95%CI: 18.40-
19.14), and also, between WHO stage I&II (19.68; 95%CI: 19.24-
20.13) and WHO stage IV (17.13; 95%CI: 16.49-17.77). TB co-
infection at baseline or later was also associated with increased risk 
of mortality (AHR: 2.30; 95%CI: 1.28-4.11). Study conducted in 
Uganda shows, after adjusting for a history of HIV related 
infections, the overall relative hazard for death associated with 
tuberculosis was 1.81 (95%CI: 1.24-2.65) [18]. Manosuthi et.al also 
showed patients who delayed ART for > 6 months after TB 
diagnosis had a higher mortality rate than those who initiated ART 
< 6 months after TB diagnosis [19]. Other studies in Ethiopia have 
also showed the similar relationship [10, 20]. High mortality in 
patients living with HIV/AIDS in poor countries was linked to 
concomitant TB infection [15]. This may be because TB is the 
leading cause of death worldwide, and the virulence of the 
mycobacterium increases in HIV infected patients, where the host's 
immune system is suppressed, enabling it to establish infection very 
easily [21].  
  
Different studies conducted in African countries, including Ethiopia, 
have shown a progressive change in CD4 count and weight after 
initiation of ART [9, 22]. These studies showed that the most 
significant increment in the median CD4 count occurred in the first 
six months of ART which is also the case in the current study; 
wherein a 76.2% increase from baseline median level was observed 
in the 1st six months. The recovery in weight also showed a similar 
progress in the 1st six months (8% gains). However, the change in 
median CD4 and median weight in subsequent months was minimal, 
with an average gain of 17% and 1.4%, respectively. In addition, 
the immunologic recovery was much slower in patients with baseline 
AIDS defining disease [18].  





Improved survival was observed in patients taking ART in Somali 
region of Ethiopia. However, the risk for death was higher in 
patients with bed-ridden functional status, advanced WHO stage, 
low CD4 count, severe anemia, low BMI, and concomitant TB 
infection. Intensive clinical and nutritional rehabilitation is 
recommended during the earliest follow up periods on ART for 
patients with these prognostic factors. Providing screening and 
chemoprophylaxis for TB to patients on ART is insurmountable in 
deterring the infection and decreasing mortality. Optimal 
immunologic and weight recoveries occurred in the first six months 
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Table 1: socio-demographic characteristics of adult PLHIV receiving ART in Somali region, Ethiopia 
(N=784), May 2013 
Variables Total (N, %) Dead (N, %) Active (N, %) Log-rank P 
Sex         
Male 326 (41.6%) 46 (52.9%) 280 (40.2%) 
0.019 
Female 458 (58.4%) 41 (47.1%) 417 (59.8%) 
Age category         
15-24 108 (13.8%) 6 (6.9%) 102 (14.6%) 
0.249 
25-34 327 (41.7%) 41 (47.1%) 102 (14.6%) 
35-44 229 (29.2%) 25 (28.7%) 204 (29.3%) 
45+ 120 (15.3%) 15 (17.2%) 105 (15.1%) 
Religion         
Muslim 319 (40.7%) 35 (11.0%) 284 (89.0%) 
0.714 Orthodox 438 (55.9%) 50 (11.4%) 388 (88.6%) 
Protestant 27 (3.4%) 2 (7.4%) 25 (92.6%) 
Marital status         
Married 325 (41.5%) 27 (31.0%) 298 (42.8%) 
0.002 
Single 115 (14.7%) 24 (27.6%) 91 (13.1%) 
Separated 27 (3.4%) 1 (1.1%) 26 (3.7%) 
Divorced 226 (28.8%) 26 (29.9%) 200 (28.7%) 
Widowed 91 (11.6%) 9 (10.3%) 82 (11.8%) 
Educational status         
No education 297 (37.9%) 48 (55.2%) 249 (35.7%) 
0.000 
Primary 217 (27.7%) 27 (31.0%) 190 (27.3%) 
Secondary 207 (26.4%) 10 (11.5%) 197 (28.3%) 
College/Above 63 (8.0%) 2 (2.3%) 61 (8.8%) 
Dependent children         
Yes 455 (58.0%) 52 (59.8%) 403 (57.8%) 
0.889 
No 329 (42.0%) 35 (40.2%) 294 (42.2%) 
ART Adherence         
Good 431 (55.0%) 36 (41.4%) 395 (56.7%) 
0.000 Fair 431 (55.0%) 20 (23.0%) 157 (22.5%) 
Poor 176 (22.4%) 31 (35.6%) 145 (20.8%) 
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Table 2: clinical and laboratory markers of adult PLHIV receiving ART in Somali region, Ethiopia (N=784), May 2013 
Variables Total (N, %) Dead (N, %) Active (N, %) Log-rank P 
Functional status         
Working 434 (55.4%) 12 (13.8%) 422 (60.5%) 
0.000 Ambulatory 242 (30.9%) 37 (42.5%) 205 (29.4%) 
Bedridden 108 (13.8%) 38 (43.7%) 70 (10.0%) 
WHO staging         
Stage I & II 329 (42.0%) 10 (11.5%) 319 (45.8%) 
0.000 Stage III 327 (41.7%) 38 (43.7%) 289 (41.5%) 
Stage IV 128 (16.3%) 39 (44.8%) 89 (12.8%) 
BMI for age         
≥18.5 Kg/m2 335 (42.7%) 23 (26.4%) 312 (44.8%) 
0.000 
< 18.5 Kg/m2 449 (57.3%) 64 (73.6%) 385 (55.2%) 
Cotrimoxazole         
Given 658 (83.9%) 66 (75.9%) 592 (84.9%) 
0.032 
Not given 126 (16.1%) 21 (24.1%) 105 (15.1%) 
INH Given         
Given 61 (7.8%) 20 (23.0%) 41 (5.9%) 
0.000 
Not given 723 (92.2%) 67 (77.0%) 656 (98.3%) 
TB co-infected         
Yes 311 (39.7%) 45 (51.7%) 266 (38.2%) 
0.015 
No 473 (60.3%) 42 (48.3%) 431 (61.8%) 
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Table 3: predictors of mortality among adult PLHIV receiving ART in Somali region, Ethiopia (N=784), May 
2013 
Variables Crude HR (95% CI) P value AHR (95% CI) P value 
Marital status         
Married 1 - 1 - 
Single 2.69 (1.55, 4.66) 0.001 2.31 (1.18, 4.50) 0.015 
Separated 0.40 (0.05, 2.94) 0.367 0.13 (0.014, 1.21) 0.073 
Divorced 1.41 (0.82, 2.41) 0.215 1.47 (0.80, 2.71) 0.215 
Widowed 1.15 (0.54, 2.44) 0.719 1.27 (0.56, 2.86) 0.566 
Educational status         
No education 5.66 (1.38, 23.29) 0.016 4.73 (1.07, 22.40) 0.038 
Primary 4.26 (1.01, 17.91) 0.048 3.83 (0.80, 18.30) 0.082 
Secondary 1.54 (0.34, 7.05) 0.575 2.43 (0.50, 12.01) 0.281 
College/Above 1 - 1 - 
Functional status         
Working 1 - 1 - 
Ambulatory 6.16 (3.21, 11.82) 0.000 2.12 (1.05, 4.26) 0.035 
Bedridden 15.42 (8.05, 29.53) 0.000 5.91 (2.87, 12.16) 0.000 
WHO staging         
Stage I&II 1 - 1 - 
Stage III 5.28 (2.60, 10.71) 0.000 4.00 (1.83, 8.74) 0.000 
Stage IV 16.22 (7.93, 33.20) 0.000 7.36 (3.17, 17.12) 0.000 
BMI for age         
≥18.5 Kg/m2 1 - 1   
< 18.5 Kg/m2 2.27 (1.41, 3.66) 0.001 2.20 (1.18, 4.09) 0.013 
CD4 category         
≥ 200 1 - 1 - 
125-200 3.87 (2.05, 7.27) 0.000 1.33 (0.65, 2.72) 0.440 
50-125 5.62 (3.04, 10.41) 0.000 2.24 (1.08, 4.65) 0.031 
< 50 17.36 (9.96, 30.28) 0.000 2.70 (1.26, 5.80) 0.011 
Anemia         
Normal 1 - 1 - 
Mild 1.16 (0.56, 2.42) 0.695 1.16 (0.52, 2.60) 0.724 
Moderate 3.27 (1.69, 6.32) 0.000 2.90 (1.36, 6.16) 0.006 
Severe 8.01 (4.53, 14.17) 0.000 4.57 (2.30, 9.10) 0.000 
TB co-infected         
Yes 2.21 (1.35, 3.62) 0.002 2.30 (1.28, 4.11) 0.005 




Figure 1: Cumulative survival of adult PLHIV receiving ART in Somali region, 
Ethiopia, May 2013  
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Figure 2: Median weight change during follow-up for adult PLHIV receiving ART in Somali region, 






Figure 3: Median CD4 change during follow-up for adult PLHIV receiving ART in Somali region, Ethiopia, 
May 2013 
 
 
 
 
